Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29264
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ruwanpura S.M. | en |
dc.contributor.author | Bardin P.G. | en |
dc.contributor.author | Thomas B.J. | en |
dc.date.accessioned | 2021-05-14T09:52:57Z | en |
dc.date.available | 2021-05-14T09:52:57Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200630 | en |
dc.date.issued | 2020-06-30 | en |
dc.identifier.citation | American Journal of Respiratory Cell and Molecular Biology. 62 (4) (pp 413-422), 2020. Date of Publication: 2020. | en |
dc.identifier.issn | 1044-1549 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/29264 | en |
dc.description.abstract | Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was initially developed as an antiinflammatory compound because of its ability to diminish the accumulation of inflammatory cells and cytokines. Despite recent studies that have elucidated key mechanisms, the precise molecular activities of PFD remain incompletely understood. PFD modulates fibrogenic growth factors, thereby attenuating fibroblast proliferation, myofibroblast differentiation, collagen and fibronectin synthesis, and deposition of extracellular matrix. This effect is mediated by suppression of TGF-b1 (transforming growth factor-b1) and other growth factors. Here, we appraise the impact of PFD on TGF-b1 production and its downstream pathways. Accumulating evidence indicates that PFD also downregulates inflammatory pathways and therefore has considerable potential as a viable and innovative antiinflammatory compound. We examine the effects of PFD on inflammatory cells and the production of pro- and antiinflammatory cytokines in the lung. In this context, recent evidence that PFD can target inflammasome pathways and ensuing lung inflammation is highlighted. Finally, the antioxidant properties of PFD, such as its ability to inhibit redox reactions and regulate oxidative stress-related genes and enzymes, are detailed. In summary, this narrative review examines molecular mechanisms underpinning PFD and its recognized benefits in lung fibrosis. We highlight preclinical data that demonstrate the potential of PFD as a nonsteroidal antiinflammatory agent and outline areas for future research.Copyright © 2020 by the American Thoracic Society. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | American Thoracic Society (E-mail: malexander@thoracic.org) | en |
dc.relation.ispartof | American Journal of Respiratory Cell and Molecular Biology | en |
dc.subject.mesh | antiinflammatory activity | - |
dc.subject.mesh | drug effect | - |
dc.subject.mesh | inflammatory cell | - |
dc.subject.mesh | lung disease | - |
dc.subject.mesh | lung fibrosis | - |
dc.subject.mesh | antifibrotic activity | - |
dc.subject.mesh | pirfenidone | - |
dc.subject.mesh | transforming growth factor beta1 | - |
dc.subject.mesh | pharmacology | - |
dc.subject.mesh | cytokine | - |
dc.subject.mesh | inflammasome | - |
dc.subject.mesh | pirfenidone | - |
dc.title | Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease. | en |
dc.type | Review | en |
dc.identifier.affiliation | Respiratory and Sleep Medicine | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1165/rcmb.2019-0328TR | - |
dc.publisher.place | United States | en |
dc.identifier.pubmedid | 31967851 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31967851] | en |
dc.identifier.source | 2005468824 | en |
dc.identifier.institution | (Ruwanpura, Thomas, Bardin) Monash Lung and Sleep, Monash Health, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia (Thomas, Bardin) Hudson Institute of Medical Research, Clayton, VIC, Australia | en |
dc.description.address | S.M. Ruwanpura, Monash Lung and Sleep, Monash Health, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia. E-mail: saleela.ruwanpura@monash.edu | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Fibrosis Inflammation Oxidative stress in lung Pirfenidone | en |
dc.identifier.authoremail | Ruwanpura S.M.; saleela.ruwanpura@monash.edu | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.